Journal article
Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
Abstract
Vitamin K antagonists (VKAs) are effective for stroke prevention in patients with atrial fibrillation (AF) but are difficult to use. Dabigatran etexilate is a prodrug that is rapidly converted to the active direct thrombin inhibitor dabigatran. It is administered in a fixed dose without laboratory monitoring and is being compared with warfarin (international normalized ratio 2-3) in the RE-LY trial. Two doses of dabigatran (110 and 150 mg BID) …
Authors
Ezekowitz MD; Connolly S; Parekh A; Reilly PA; Varrone J; Wang S; Oldgren J; Themeles E; Wallentin L; Yusuf S
Journal
American Heart Journal, Vol. 157, No. 5, pp. 805–810.e2
Publisher
Elsevier
Publication Date
5 2009
DOI
10.1016/j.ahj.2009.02.005
ISSN
0002-8703
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, OralAgedAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationBenzimidazolesDabigatranDose-Response Relationship, DrugDouble-Blind MethodEchocardiography, TransesophagealElectric CountershockFollow-Up StudiesHumansIntracranial ThrombosisProspective StudiesPyridinesResearch DesignRisk FactorsStrokeTime FactorsTreatment OutcomeWarfarin